This study will investigate the use of anecortave acetate injection to reduce intraocular pressure (IOP) in corneal transplant recipients who are experiencing steroid-associated pressure control problems. Alternative methods of IOP control have been shown to entail serious risks. For example, reduction of topical steroids increases the risk of graft rejection, and use of glaucoma medications or glaucoma surgery increases the risk of graft failure. This study is designed to have sufficient power to detect whether a single injection can induce a clinically significant IOP reduction.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
7
anterior juxtascleral depot of 15 mg anecortave acetate
anterior juxtascleral depot of 30mg anecortave acetate
Price Vision Group
Indianapolis, Indiana, United States
Intraocular Pressure Within Normal Limits (<24 mm Hg)
Intraocular pressure was measured by Goldmann applanation tonometry.
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.